Blood Glucose Control and Insulin Secretion Improved With Combined Therapy in Type 2 Diabetic Patients With Secondary Failure to Oral Hypoglycaemic Agents

Publisher Website
Google Scholar
Abstract
The influence of combined therapy using insulin and oral hypoglycaemic agents on blood glucose control and on insulin secretion in Type 2 diabetic patients with secondary failure to oral hypoglycaemic agents was evaluated. Type 2 diabetic patients (n = 180) (98 normal‐weight, 82 over‐weight), at least 3 years from diagnosis, and having poor blood glucose control on oral hypoglycaemic agents for at least 3 months (fasting plasma glucose > 10.0 mmol l−1) despite intensive efforts at improvement, were included in the study. A single daily insulin injection (human ultralente), at a dose of 0.22 ± 0.07 U kg−1 d−1 in normal‐weight and 0.33 ± 0.10 U kg−1 d−1 in over‐weight patients, was added to the previous dietary and drug treatment for 6 months. A progressive and significant (2p < 0.001) reduction of the mean daily blood glucose was observed during the first 3 months of combined therapy (from 13.2 ± 3.2 to 8.1 ± 2.1 mmol l−1 in normal‐weight and from 13.4 ± 3.1 to 8.8 ± 2.3 mmol l−1 in over‐weight patients), with no further significant changes thereafter. A significant increase (2p < 0.001) in the mean daily C‐peptide concentration (from 0.50 ± 0.30 to 0.71 ± 0.29 nmol l−1 in normal‐weight and from 0.78 ± 0.36 to 1.00 ± 0.41 nmol l−1 in over‐weight patients) took place during combined therapy. No changes of body weight (+ 1.5 ± 1.2 kg in normal‐weight and +1.0 ± 1.0 kg in over‐weight patients) were observed.